NO940266L - Indre strålingsskade - Google Patents

Indre strålingsskade

Info

Publication number
NO940266L
NO940266L NO940266A NO940266A NO940266L NO 940266 L NO940266 L NO 940266L NO 940266 A NO940266 A NO 940266A NO 940266 A NO940266 A NO 940266A NO 940266 L NO940266 L NO 940266L
Authority
NO
Norway
Prior art keywords
radiation damage
internal radiation
dgla
gla
treatment
Prior art date
Application number
NO940266A
Other languages
English (en)
Other versions
NO940266D0 (no
Inventor
David Frederick Horrobin
Catherine Ann Scott
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of NO940266D0 publication Critical patent/NO940266D0/no
Publication of NO940266L publication Critical patent/NO940266L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Skader på indre vev, og da spesielt på det sentrale nervesystemet som en konsekvens av eksponering overfor ioniserende stråling, hindres eller behandles ved å tilføre GLA og/eller DGLA. Medikamenter som inneholder GLA og/eller DGLA for slik behandling eller for profylaktisk behandling, kan videre også inneholde EPA og/eller DHA.
NO940266A 1993-01-26 1994-01-25 Indre strålingsskade NO940266L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939301446A GB9301446D0 (en) 1993-01-26 1993-01-26 Internal radiation damage

Publications (2)

Publication Number Publication Date
NO940266D0 NO940266D0 (no) 1994-01-25
NO940266L true NO940266L (no) 1994-07-27

Family

ID=10729293

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940266A NO940266L (no) 1993-01-26 1994-01-25 Indre strålingsskade

Country Status (12)

Country Link
US (2) US5583159A (no)
EP (1) EP0609064A1 (no)
JP (1) JPH06279277A (no)
KR (1) KR940018089A (no)
CN (1) CN1104496A (no)
AU (1) AU673868B2 (no)
CA (1) CA2114047A1 (no)
GB (1) GB9301446D0 (no)
NO (1) NO940266L (no)
NZ (1) NZ250757A (no)
RU (1) RU94002337A (no)
ZA (1) ZA94392B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9621373D0 (en) * 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
EP1090165A2 (de) * 1998-05-28 2001-04-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Schichtsystem zum korrosionsschutz von leichtmetallen und leichtmetalllegierungen
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
EP1372641A4 (en) 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
EP2324828A1 (en) * 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
US7537572B2 (en) * 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
WO2012087113A1 (en) 2010-12-24 2012-06-28 N.V. Nutricia Improved nutritional tablet
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
WO2018009700A1 (en) * 2016-07-06 2018-01-11 Waters Technologies Corporation Monitoring radiation exposure and radiosensitivity using ambient ionization mass spectrometry
US12171728B2 (en) 2018-04-16 2024-12-24 S&R Farmaceutici S.P.A. Mixture of resveratrol supported on metal hydroxide and non-supported pure resveratrol for treating female fertility
RU2734243C1 (ru) * 2019-07-23 2020-10-13 федеральное государственное бюджетное научное учреждение "Федеральный центр токсикологической, радиационной и биологической безопасности" (ФГБНУ "ФЦТРБ-ВНИВИ") Способ лечения радиационных поражений организма
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69782A (en) * 1982-09-22 1987-12-20 Sentrachem Ltd Compositions for preventing cancerous conditions comprising precursors of eicosanoid mixtures and a dietary supplement containing them
GB8522670D0 (en) * 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
ES2032574T3 (es) * 1987-01-19 1993-02-16 Parfums Rochas Nuevas composiciones cosmeticas o dermatologicas que contienen un extracto de frutos de "silybum marianum", rico en silimarina, asociado a acidos grasos esenciales. (reserva del art. 167.2 cpe).
DE3863678D1 (de) * 1987-04-27 1991-08-22 Efamol Holdings Lithiumsalze enthaltende pharmazeutische zubereitungen.
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
US5271925A (en) * 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound

Also Published As

Publication number Publication date
ZA94392B (en) 1994-09-01
EP0609064A1 (en) 1994-08-03
CN1104496A (zh) 1995-07-05
AU5395894A (en) 1994-08-04
CA2114047A1 (en) 1994-07-27
NZ250757A (en) 1997-06-24
KR940018089A (ko) 1994-08-16
US5583159A (en) 1996-12-10
NO940266D0 (no) 1994-01-25
GB9301446D0 (en) 1993-03-17
JPH06279277A (ja) 1994-10-04
AU673868B2 (en) 1996-11-28
RU94002337A (ru) 1996-08-27
US5663202A (en) 1997-09-02

Similar Documents

Publication Publication Date Title
AU610036B2 (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
NO982310L (no) Protegriner
DE59509751D1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
RU93048466A (ru) Применение бензотиофенов для профилактики и лечения остеопороза и фармацевтическая композиция на их основе
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
DE122006000010I2 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in derBehandlung von kardiovaskularen Krankheiten
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
EP0303915A3 (en) Retinoids for the treatment of skin damaged by light
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
NO912548D0 (no) Fremgangsmaate for behandling av avfallsprodukter.
HU9500933D0 (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
NO890046D0 (no) Disubstituerte pyridiner.
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
GB2271509A8 (en) Antivenom immunesera
NO982582L (no) Fremgangsmaate for behandling av smerte
GR3017967T3 (en) Substituted pyrido-oxazines.
NO940400L (no) Farmasöytisk preparat inneholdene karbakol og andre kolinergiske stoffer
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
RU95113977A (ru) Средство для лечения ран
EP0342427A3 (de) Strobilurinderivate, ihre Herstellung und Verwendung